Taconic Biosciences, Inc.

Taconic Biosciences, Inc. is a leading provider of genetically engineered rodent models, enabling critical preclinical research across various therapeutic areas such as oncology, neuroscience, and immunology. Founded in 1952 in New York, US, Taconic Biosciences, Inc. specializes in providing genetically engineered rodent models that are essential for drug discovery.

The company was acquired by Avista Capital Partners from H. I. G. Capital in November 2022.

The firm has engaged in two defined funding deals to date. The current CEO is Nancy Sandy, with Andrew Russell also holding a leadership role. Taconic Biosciences specializes in developing and providing genetically engineered rodent models, including super immunodeficient NOG mice and humanized immune system (HIS) mice. These models support preclinical research in oncology, neuroscience, and immunology, catering to pharmaceutical companies, academic institutions, and non-profit organizations globally.

Taconic Biosciences generates revenue primarily through B2B partnerships with pharmaceutical and academic institutions. Clients typically purchase rodent models directly and may utilize custom model generation services. The pricing structure accommodates various clients, including government and non-profit organizations that can receive discounts up to 35%. Flagship products like the FcResolv® NOG portfolio are key to their revenue, facilitating repeat orders and long-term collaborations within the scientific community.

Following the acquisition in November 2022, Taconic Biosciences, Inc. plans to leverage its resources for organic growth and strategic acquisitions, focusing on expansion in the large genetically engineered models market. Specific information regarding new products is not disclosed; however, the company aims to enhance its market presence in upcoming years.